非小细胞肺癌分子靶向维持治疗的时机到了吗？ - Suppr

Suppr

超能文献

Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?

作者信息

Stinchcombe Thomas E, Ramalingam Suresh S

出版信息

Lancet Oncol. 2010 Jun;11(6):500-1. doi: 10.1016/S1470-2045(10)70120-0. Epub 2010 May 20.

DOI:10.1016/S1470-2045(10)70120-0

PMID:20493770

Abstract

摘要

相似文献

Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?

Lancet Oncol. 2010 Jun;11(6):500-1. doi: 10.1016/S1470-2045(10)70120-0. Epub 2010 May 20.

Clairvoyance or reliable prediction of the future?

Ann Oncol. 2007 Mar;18(3):407-8. doi: 10.1093/annonc/mdl503.

NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.

Lancet Oncol. 2012 Aug;13(8):764-5. doi: 10.1016/s1470-2045(12)70296-6.

Molecular selection trumps clinical selection.

J Clin Oncol. 2011 Jul 20;29(21):2843-4. doi: 10.1200/JCO.2011.35.9208. Epub 2011 Jun 13.

Personalized medicine and inhibition of EGFR signaling in lung cancer.

N Engl J Med. 2009 Sep 3;361(10):1018-20. doi: 10.1056/NEJMe0905763. Epub 2009 Aug 19.

Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.

Clin Lung Cancer. 2005 Jan;6(4):214-6. doi: 10.1016/s1525-7304(11)70473-9.

Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.

Nat Rev Clin Oncol. 2010 Nov;7(11):618-9. doi: 10.1038/nrclinonc.2010.168.

Medical treatment of non-small-cell lung cancer.

Ann Oncol. 2005;16 Suppl 2:ii229-32. doi: 10.1093/annonc/mdi721.

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

J Clin Oncol. 2008 Mar 1;26(7):1182-4; author reply 1184-6. doi: 10.1200/JCO.2007.14.9039.

Histology matters: individualizing treatment in non-small cell lung cancer.

Oncologist. 2010;15(1):3-5. doi: 10.1634/theoncologist.2009-0306. Epub 2010 Jan 19.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?

作者信息

Stinchcombe Thomas E, Ramalingam Suresh S

出版信息

Lancet Oncol. 2010 Jun;11(6):500-1. doi: 10.1016/S1470-2045(10)70120-0. Epub 2010 May 20.

DOI:10.1016/S1470-2045(10)70120-0

PMID:20493770

Abstract

摘要

相似文献

Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?

Lancet Oncol. 2010 Jun;11(6):500-1. doi: 10.1016/S1470-2045(10)70120-0. Epub 2010 May 20.

Clairvoyance or reliable prediction of the future?

Ann Oncol. 2007 Mar;18(3):407-8. doi: 10.1093/annonc/mdl503.

NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.

Lancet Oncol. 2012 Aug;13(8):764-5. doi: 10.1016/s1470-2045(12)70296-6.

Molecular selection trumps clinical selection.

J Clin Oncol. 2011 Jul 20;29(21):2843-4. doi: 10.1200/JCO.2011.35.9208. Epub 2011 Jun 13.

Personalized medicine and inhibition of EGFR signaling in lung cancer.

N Engl J Med. 2009 Sep 3;361(10):1018-20. doi: 10.1056/NEJMe0905763. Epub 2009 Aug 19.

Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.

Clin Lung Cancer. 2005 Jan;6(4):214-6. doi: 10.1016/s1525-7304(11)70473-9.

Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.

Nat Rev Clin Oncol. 2010 Nov;7(11):618-9. doi: 10.1038/nrclinonc.2010.168.

Medical treatment of non-small-cell lung cancer.

Ann Oncol. 2005;16 Suppl 2:ii229-32. doi: 10.1093/annonc/mdi721.

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

J Clin Oncol. 2008 Mar 1;26(7):1182-4; author reply 1184-6. doi: 10.1200/JCO.2007.14.9039.

Histology matters: individualizing treatment in non-small cell lung cancer.

Oncologist. 2010;15(1):3-5. doi: 10.1634/theoncologist.2009-0306. Epub 2010 Jan 19.